Limits...
Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction.

Lorente L, Martín MM, González-Rivero AF, Ramos L, Argueso M, Cáceres JJ, Solé-Violán J, Jiménez A, Borreguero-León JM - Int J Mol Sci (2015)

Bottom Line: We found higher serum sCD154 levels in patients with severe MMCAI than in healthy controls (p < 0.001).We found higher serum sCD154 levels (p < 0.001) in non-surviving (n = 26) than in surviving MMCAI patients (n = 24).The new more important finding of our study was that serum sCD154 levels in MMCAI patients were associated with mortality.

View Article: PubMed Central - PubMed

Affiliation: Intensive Care Unit, Hospital Universitario de Canarias, La Laguna 38320, Spain. lorentemartin@msn.com.

ABSTRACT

Background: CD154 and its soluble counterpart (sCD154) are proteins of the tumor necrosis factor (TNF) family and exhibit proinflamatory and procoagulant properties. Higher circulating sCD154 levels have been found in ischemic stroke patients than in controls. However, the association between circulating sCD154 levels and mortality in ischemic stroke patients has not been reported, and was the focus of this study.

Methods: This was a multicenter, observational and prospective study carried out in six Spanish Intensive Care Units. We measured serum sCD154 from 50 patients with severe malignant middle cerebral artery infarction (MMCAI), defined as Glasgow Coma Scale (GCS) lower than 9, at the moment of the severe MMCAI diagnosis and from 50 healthy controls. The end-point of the study was 30-day mortality.

Results: We found higher serum sCD154 levels in patients with severe MMCAI than in healthy controls (p < 0.001). We found higher serum sCD154 levels (p < 0.001) in non-surviving (n = 26) than in surviving MMCAI patients (n = 24). Multiple binomial logistic regression analysis showed that serum sCD154 levels >1.41 ng/mmL were associated with 30-day mortality (OR = 10.25; 95% CI = 2.34-44.95; p = 0.002).

Conclusions: The new more important finding of our study was that serum sCD154 levels in MMCAI patients were associated with mortality.

No MeSH data available.


Related in: MedlinePlus

Survival curves at 30 days using serum sCD154 levels higher or lower than 1.41 ng/mL.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4490435&req=5

ijms-16-12147-f003: Survival curves at 30 days using serum sCD154 levels higher or lower than 1.41 ng/mL.

Mentions: Figure 3 shows survival analysis of patients with serum sCD154 levels higher and lower of 1.41 ng/mmL, and survival at 30 days as the dependent variable. We found that patients with serum sCD154 levels higher than 1.41 ng/mmL showed higher mortality at 30 days than patients with lower levels (Hazard ratio = 3.4; 95% CI = 1.58–7.39; p = 0.006).


Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction.

Lorente L, Martín MM, González-Rivero AF, Ramos L, Argueso M, Cáceres JJ, Solé-Violán J, Jiménez A, Borreguero-León JM - Int J Mol Sci (2015)

Survival curves at 30 days using serum sCD154 levels higher or lower than 1.41 ng/mL.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4490435&req=5

ijms-16-12147-f003: Survival curves at 30 days using serum sCD154 levels higher or lower than 1.41 ng/mL.
Mentions: Figure 3 shows survival analysis of patients with serum sCD154 levels higher and lower of 1.41 ng/mmL, and survival at 30 days as the dependent variable. We found that patients with serum sCD154 levels higher than 1.41 ng/mmL showed higher mortality at 30 days than patients with lower levels (Hazard ratio = 3.4; 95% CI = 1.58–7.39; p = 0.006).

Bottom Line: We found higher serum sCD154 levels in patients with severe MMCAI than in healthy controls (p < 0.001).We found higher serum sCD154 levels (p < 0.001) in non-surviving (n = 26) than in surviving MMCAI patients (n = 24).The new more important finding of our study was that serum sCD154 levels in MMCAI patients were associated with mortality.

View Article: PubMed Central - PubMed

Affiliation: Intensive Care Unit, Hospital Universitario de Canarias, La Laguna 38320, Spain. lorentemartin@msn.com.

ABSTRACT

Background: CD154 and its soluble counterpart (sCD154) are proteins of the tumor necrosis factor (TNF) family and exhibit proinflamatory and procoagulant properties. Higher circulating sCD154 levels have been found in ischemic stroke patients than in controls. However, the association between circulating sCD154 levels and mortality in ischemic stroke patients has not been reported, and was the focus of this study.

Methods: This was a multicenter, observational and prospective study carried out in six Spanish Intensive Care Units. We measured serum sCD154 from 50 patients with severe malignant middle cerebral artery infarction (MMCAI), defined as Glasgow Coma Scale (GCS) lower than 9, at the moment of the severe MMCAI diagnosis and from 50 healthy controls. The end-point of the study was 30-day mortality.

Results: We found higher serum sCD154 levels in patients with severe MMCAI than in healthy controls (p < 0.001). We found higher serum sCD154 levels (p < 0.001) in non-surviving (n = 26) than in surviving MMCAI patients (n = 24). Multiple binomial logistic regression analysis showed that serum sCD154 levels >1.41 ng/mmL were associated with 30-day mortality (OR = 10.25; 95% CI = 2.34-44.95; p = 0.002).

Conclusions: The new more important finding of our study was that serum sCD154 levels in MMCAI patients were associated with mortality.

No MeSH data available.


Related in: MedlinePlus